NuCana (NASDAQ: NCNA) plans ESMO 2025 cancer research presentation

Rhea-AI Filing Summary

NuCana plc reported that it will give a presentation at the European Society for Medical Oncology (ESMO) Congress 2025, which takes place October 17-21, 2025 in Berlin, Germany. This update comes via a company press release dated September 3, 2025, which is included as an exhibit to the report. The content of the press release is furnished for informational purposes and is not treated as filed under U.S. securities law unless specifically incorporated into other company disclosures.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

(Commission File No. 001-38215)

NUCANA PLC

(Translation of registrant’s name into English)

3 Lochside Way

Edinburgh EH12 9DT

United Kingdom

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐

Other Events

On September 3, 2025, NuCana plc (the “Company”) issued a press release announcing that it will make a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 being held October 17-21, 2025 in Berlin, Germany. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

Exhibits

99.1 Press Release, dated September 3, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NuCana plc
By:		/s/ Ian Webster
Name:		Ian Webster
Title:		Interim Chief Financial Officer (Principal Financial and Accounting Officer)

Date: September 3, 2025

FAQ

What did NuCana (NCNA) announce in this report?

NuCana plc announced that it will make a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.

When and where is NuCana (NCNA) presenting at ESMO 2025?

The company plans to present at the ESMO Congress 2025, which will be held October 17-21, 2025 in Berlin, Germany.

How did NuCana (NCNA) communicate its ESMO 2025 plans?

NuCana issued a press release dated September 3, 2025, describing its planned presentation at ESMO 2025; this press release is attached as Exhibit 99.1.

Is the NuCana (NCNA) ESMO 2025 press release considered filed with the SEC?

The company states that the information in Exhibit 99.1 is being furnished and is not deemed filed under Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference in another document.

Who signed this NuCana (NCNA) report?

The report was signed on behalf of NuCana plc by Ian Webster, who is identified as Interim Chief Financial Officer and Principal Financial and Accounting Officer.

Does this NuCana (NCNA) report include financial results or earnings data?

No, this report focuses on NuCana’s planned presentation at the ESMO Congress 2025 and references the related press release; it does not present financial or earnings figures.